

## Special Issue

# Genomics-Guided Radiotherapy in Cancer

### Message from the Guest Editors

We are pleased to invite you to contribute to this Special Issue on Genomics-Guided Radiotherapy in Cancer.

Advances in human genomics have enabled personalized medicine in oncology, guiding screening, prognosis, and treatment selection to improve cancer outcomes. In Radiation Oncology, recent advances in uncovering the genomic basis of tumor and tissue response to radiation could be used to guide patient selection, optimize radiotherapy plans, inform targeted use of increasingly conformal radiation modalities, and point to novel radiobiologic mechanisms for development of new sensitizing or mitigating agents. This Special Issue aims to highlight the current state of the science in malignant and normal tissue radiation response with a focus on future prospects for improving personalization of treatment planning and development of mechanistically targeted tumor radiosensitizers and normal tissue radioprotectors. Original research articles and reviews are welcome.

We look forward to receiving your contributions.

---

### Guest Editors

Dr. Sarah L. Kerns

Medical College of Wisconsin, Milwaukee, WI 53226, USA

Dr. William A. Hall

Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226, USA

---

### Deadline for manuscript submissions

closed (31 December 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/129805](https://mdpi.com/si/129805)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)